Controversies in Internal Medicine
March 24, 2003

Should Routine Screening for Prostate-Specific Antigen Be Recommended?

Author Affiliations

From the Division of Urology, University of Colorado Health Sciences Center, Denver. The authors have no relevant financial interest in this article.




Copyright 2003 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2003

Arch Intern Med. 2003;163(6):661-663. doi:10.1001/archinte.163.6.661

ROUTINE SCREENING for prostate cancer remains a controversial topic. Prostate cancer is the most common cause of cancer of men in the United States and caused more than 30 000 deaths in 1999. It involves a wide pathophysiologic spectrum, from indolent disease to rapid growth and metastasis. A continued increase in frequency of prostate cancer is expected as the baby boom generation reaches the higher-risk age range for the disease. The main approaches to manage the disease include prevention, early detection (screening) and treatment, and effective treatment of advanced and/or metastatic disease. Currently, prostate-specific antigen (PSA) is the most important tumor marker for the detection, staging, and monitoring of men with prostate cancer.1

First Page Preview View Large
First page PDF preview
First page PDF preview